ImpediMed has completed its capital raising which should see it through cash-wise to end FY21, the broker suggests. The March quarter featured a growing installed base, recurring revenues and test volumes, the broker notes, and the transition to SaaS appears to be on track.

Adjusting for more conservative test volume assumptions, and share price dilution, the broker drops its target to 14c from 26c, retaining a Speculative Buy rating.

Sector: Health Care Equipment & Services.

Target price is $0.14.Current Price is $0.04. Difference: $0.10 - (brackets indicate current price is over target). If IPD meets the Morgans target it will return approximately 71% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena